The drug regulator for the European Union has stated that its longer approval process for COVID-19 vaccines is safer, Reuters news agency reported on Wednesday.
Emergency authorisation of Pfizer and BioNTech's COID-19 vaccine has been granted by the UK regulator.
Reuters quoted the European Medicines Agency as saying: "EMA considers that the conditional marketing authorisation is the most appropriate regulatory mechanism for use in the current pandemic emergency."
It added that procedure was based on more evidence and more checks than the emergency procedure chosen by the UK.
EMA has said that it will decide on authorisation of Pfizer's vaccine by 29 December 2020.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT